The company is evaluating sustained-release injectable anti-VEGF drug depots along with using its proprietary hydrogel platform technology for anterior segment disorders (specifically pain and inflammation).
The company’s OTX drug-eluting punctal plug is a non-invasive procedure that will eliminate drops (and the potential non-compliance). Two phase 3 studies have been completed on inflammation, with 39.4% absence of anterior chamber cells at day 14, and absence of pain at day 8 in 77.5% of patients. OTX-DP (dexamethasone) has completed phase 2 for allergy and will be moving into phase 3; a phase 2 study on inflammatory dry eye is ongoing. OTX-TP (travoprost) is in phase 2 studies for glaucoma with results expected by the end of the year, and OTX-MP (moxifloxacin) is in early studies for bacterial conjunctivitis. Allergy studies have shown some “good separation” in itching and redness compared to placebo, Sawhney said.
Finally, the company is developing a sustained release bevacizumab product.
The company’s first product, ReSure Sealant, is commercially available.
Amar Sawhney, PhD
Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006, has since served as President and CEO and was elected Chairman of the Board in 2014.
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.